Risk factors for SARS-CoV-2 infection and transmission in households with children with asthma and allergy: A prospective surveillance study.

"Disclosure of potential conflict of interest: L. B. Bacharier reports grants from NIH/NIAID and NHLBI, personal fees from GlaxoSmithKline Genentech/Novartis, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi/Regeneron, Vectura, Circassia, Kinaset, and Vertex, as well as royalties from Elsevier outside the submitted work. R. S. Gupta reports research grant support from the NIH (R21 ID# AI135705, R01 ID# AI130348, U01 ID # AI138907), Allergy and Asthma Network, Food Allergy Research and Education, Melchiorre Family Foundation, Sunshine Charitable Foundation, Walder Foundation, Stanford Sean N. Parker Center for Allergy Research, UnitedHealth Group, Thermo Fisher Scientific, Genentech, and the National Confectioners Association; in addition, she has served as a medical consultant/advisor for Genentech, Novartis, and Food Allergy Research and Education; has ownership interest in YoBee Care Inc; and is currently employed by Ann and Robert H. Lurie Children's Hospital of Chicago. D. J. Jackson reports personal fees from Astra Zeneca, GlaxoSmithKline, Vifor Pharma, Sanofi, Regeneron, and Pfizer, as well as grant funding from GlaxoSmithKline outside the submitted work. S. J. Teach reports grant support from the NIH/NHLBI, NIH/NIAID, NIH/NICHD, EJF Philanthropies and Novartis, contract support from DC Health, and royalties from UptoDate, Inc. G. T. Furuta is the co-founder of EnteroTrack. L. B. Murrison is employed by and owns stock in AbbVie. M. A. Seibold reports grants from NIH/NIAID/NHLBI, and previous research funding from Genentech, Medimmune, and Pfizer. W. Phipatanakul reports NIH funding, consulting for Genentech, Novartis, Regeneron, Sanofi, GSK, and Teva, as well as asthma-related trial support from Genentech, Novartis, Regeneron, Sanofi, Merk, and Circassia. M. E. Rothenberg reports that he is a consultant for Pulm One, Spoon Guru, ClostraBio, Serpin Pharm, Allakos, Celldex, Bristol Myers Squibb, Astra Zeneca, Ellodi Pharma, GlaxoSmith Kline, Regeneron/Sanofi, Revolo Biotherapeutics, and Guidepoint and has an equity interest in the first 6 entities listed, and royalties from reslizumab (Teva Pharmaceuticals), PEESSv2 (Mapi Research Trust) and UpToDate. M. E. Rothenberg is an inventor of patents owned by Cincinnati Children’s Hospital. The remaining authors declare that they have no relevant conflicts of interest."

"Disclosure of potential conflict of interest: L. B. Bacharier reports grants from NIH/NIAID and NHLBI, personal fees from GlaxoSmithKline Genentech/Novartis, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi/Regeneron, Vectura, Circassia, Kinaset, and Vertex, as well as royalties from Elsevier outside the submitted work. R. S. Gupta reports research grant support from the NIH (R21 ID# AI135705, R01 ID# AI130348, U01 ID # AI138907), Allergy and Asthma Network, Food Allergy Research and Education, Melchiorre Family Foundation, Sunshine Charitable Foundation, Walder Foundation, Stanford Sean N. Parker Center for Allergy Research, UnitedHealth Group, Thermo Fisher Scientific, Genentech, and the National Confectioners Association; in addition, she has served as a medical consultant/advisor for Genentech, Novartis, and Food Allergy Research and Education; has ownership interest in YoBee Care Inc; and is currently employed by Ann and Robert H. Lurie Children's Hospital of Chicago. D. J. Jackson reports personal fees from Astra Zeneca, GlaxoSmithKline, Vifor Pharma, Sanofi, Regeneron, and Pfizer, as well as grant funding from GlaxoSmithKline outside the submitted work. S. J. Teach reports grant support from the NIH/NHLBI, NIH/NIAID, NIH/NICHD, EJF Philanthropies and Novartis, contract support from DC Health, and royalties from UptoDate, Inc. G. T. Furuta is the co-founder of EnteroTrack. L. B. Murrison is employed by and owns stock in AbbVie. M. A. Seibold reports grants from NIH/NIAID/NHLBI, and previous research funding from Genentech, Medimmune, and Pfizer. W. Phipatanakul reports NIH funding, consulting for Genentech, Novartis, Regeneron, Sanofi, GSK, and Teva, as well as asthma-related trial support from Genentech, Novartis, Regeneron, Sanofi, Merk, and Circassia. M. E. Rothenberg reports that he is a consultant for Pulm One, Spoon Guru, ClostraBio, Serpin Pharm, Allakos, Celldex, Bristol Myers Squibb, Astra Zeneca, Ellodi Pharma, GlaxoSmith Kline, Regeneron/Sanofi, Revolo Biotherapeutics, and Guidepoint and has an equity interest in the first 6 entities listed, and royalties from reslizumab (Teva Pharmaceuticals), PEESSv2 (Mapi Research Trust) and UpToDate. M. E. Rothenberg is an inventor of patents owned by Cincinnati Children’s Hospital. The remaining authors declare that they have no relevant conflicts of interest."

"We recruited households of children (aged <13 years) and teenagers (aged 13-21 years) who were participating in National Institutes of Health–funded cohorts that focused on asthma and/or allergic disease. In addition to the cohort-participating child, enrollment required a household caregiver; an additional household child and adult could also be enrolled. Self- or caregiver-collected biweekly nasal swabs were conducted between May 15, 2020, and February 1, 2021. On alternating weeks, if anyone developed symptoms, a prespecified algorithm prompted an additional illness event sampling of all household members. Full details of the study protocol are described elsewhere (National Clinical Trials identifier NCT04375761). The institutional review boards of all participating institutions and the Health and Human Services Office of Human Research Protections deemed this a public health surveillance study."